NAV

L-Gluconic Acid

Identification

Generic Name
L-Gluconic Acid
DrugBank Accession Number
DB04304
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 196.1553
Monoisotopic: 196.058302738
Chemical Formula
C6H12O7
Synonyms
  • Xylosecarboxylic acid
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UBeta-glucosidase ANot AvailablePaenibacillus polymyxa
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Medium-chain hydroxy acids and derivatives
Direct Parent
Medium-chain hydroxy acids and derivatives
Alternative Parents
Medium-chain fatty acids / Hydroxy fatty acids / Beta hydroxy acids and derivatives / Monosaccharides / Alpha hydroxy acids and derivatives / Secondary alcohols / Polyols / Monocarboxylic acids and derivatives / Carboxylic acids / Primary alcohols
show 3 more
Substituents
Alcohol / Aliphatic acyclic compound / Alpha-hydroxy acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Fatty acid / Fatty acyl / Hydrocarbon derivative
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
gulonic acid (CHEBI:16154)
Affected organisms
Not Available

Chemical Identifiers

UNII
0IK55ZPI0I
CAS number
526-97-6
InChI Key
RGHNJXZEOKUKBD-QTBDOELSSA-N
InChI
InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-5,7-11H,1H2,(H,12,13)/t2-,3+,4-,5-/m0/s1
IUPAC Name
(2S,3S,4R,5S)-2,3,4,5,6-pentahydroxyhexanoic acid
SMILES
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O

References

Synthesis Reference

Hans-Rudolf Muller, Werner Kundig, Alfred Hedinger, "Process for the simultaneous production of fructose and gluconic acid from glucose-fructose mixtures." U.S. Patent US4242145, issued November, 1957.

US4242145
General References
Not Available
PubChem Compound
6857417
PubChem Substance
46509025
ChemSpider
5256756
ChEBI
16154
ZINC
ZINC000003869787
PharmGKB
PA449770
PDBe Ligand
2UF
PDB Entries
4pbq

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility159.0 mg/mLALOGPS
logP-2.6ALOGPS
logP-3.4Chemaxon
logS-0.09ALOGPS
pKa (Strongest Acidic)3.39Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area138.45 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity38.27 m3·mol-1Chemaxon
Polarizability17.21 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.6019
Blood Brain Barrier+0.6092
Caco-2 permeable-0.897
P-glycoprotein substrateNon-substrate0.7062
P-glycoprotein inhibitor INon-inhibitor0.9734
P-glycoprotein inhibitor IINon-inhibitor0.9708
Renal organic cation transporterNon-inhibitor0.9443
CYP450 2C9 substrateNon-substrate0.86
CYP450 2D6 substrateNon-substrate0.8906
CYP450 3A4 substrateNon-substrate0.727
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9521
CYP450 2D6 inhibitorNon-inhibitor0.9485
CYP450 2C19 inhibitorNon-inhibitor0.9597
CYP450 3A4 inhibitorNon-inhibitor0.9376
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9802
Ames testNon AMES toxic0.9375
CarcinogenicityNon-carcinogens0.8442
BiodegradationReady biodegradable0.98
Rat acute toxicity1.3220 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9918
hERG inhibition (predictor II)Non-inhibitor0.9462
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0a70-9400000000-63747dc2ef7336f0970b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01ta-6930000000-d1ab162d55daadcb20f7
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-2900000000-6fda43c9fef438df3676
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-05g0-9300000000-ecedaa751adf4ecf0378
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03kc-9000000000-a137e6b37990b449d33e
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-9000000000-daba51d23da2e1f96d1e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-8599bc330d1a2d774c4e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-af7a585f71c6ec72847b
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-146.17804
predicted
DeepCCS 1.0 (2019)
[M+H]+148.57361
predicted
DeepCCS 1.0 (2019)
[M+Na]+154.48615
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Beta-glucosidase A
Kind
Protein
Organism
Paenibacillus polymyxa
Pharmacological action
Unknown
General Function
Beta-glucosidase activity
Specific Function
BglA is intracellular and cleaves cellobiose probably through inorganic phosphate mediated hydrolysis.
Gene Name
bglA
Uniprot ID
P22073
Uniprot Name
Beta-glucosidase A
Molecular Weight
51648.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52